17.08
前日終値:
$17.25
開ける:
$17.18
24時間の取引高:
2.17M
Relative Volume:
0.53
時価総額:
$1.82B
収益:
$64.52M
当期純損益:
$-95.55M
株価収益率:
-16.80
EPS:
-1.0169
ネットキャッシュフロー:
$-84.65M
1週間 パフォーマンス:
+8.03%
1か月 パフォーマンス:
+44.99%
6か月 パフォーマンス:
+89.15%
1年 パフォーマンス:
+250.00%
Personalis Inc Stock (PSNL) Company Profile
Compare PSNL vs TMO, DHR, NTRA, A, IDXX
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PSNL
Personalis Inc
|
17.08 | 1.80B | 64.52M | -95.55M | -84.65M | -1.0169 |
|
TMO
Thermo Fisher Scientific Inc
|
633.71 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
215.36 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
338.45 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
155.08 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
|
IDXX
Idexx Laboratories Inc
|
553.44 | 43.00B | 4.45B | 1.10B | 1.06B | 13.59 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-05-15 | 開始されました | Guggenheim | Buy |
| 2025-03-17 | 開始されました | Craig Hallum | Buy |
| 2023-02-06 | アップグレード | Needham | Hold → Buy |
| 2022-01-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | ダウングレード | Needham | Buy → Hold |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-09-20 | 繰り返されました | Needham | Buy |
| 2021-05-06 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2021-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-12 | 繰り返されました | Needham | Buy |
| 2020-11-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-10-19 | 開始されました | Citigroup | Buy |
| 2020-10-08 | 開始されました | BTIG Research | Buy |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2019-09-26 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 開始されました | BofA/Merrill | Neutral |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Morgan Stanley | Overweight |
| 2019-07-15 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Personalis Inc (PSNL) 最新ニュース
Tempus AI Shares Jump $3 Billion After Moderna Victory Boosts Value of $1.5 Billion Personalis Stake - TechStock²
AMERIPRISE FINANCIAL INC Trims Personalis Inc (PSNL) Stake -- Shares Trade 590% Above GF Value - GuruFocus
Why Tempus AI (TEM) Is Up 22.8% After Buying the Platform Behind a Key mRNA Cancer Win - simplywall.st
Deep Track Capital, LP Trims Personalis Inc (PSNL) Stake -- Shar - GuruFocus
Personalis secures new Million Veteran Program task order - TipRanks
Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP - TradingView
Personalis wins up to $18.3M VA MVP task order, cumulative VA awards reach $243.3M - TradingView
Personalis (NASDAQ: PSNL) wins Million Veteran Program task order—how big is it? - Stock Titan
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight - Stocktwits
Tempus soars on coattails of Moderna/Merck cancer vaccine - Crain's Chicago Business
Personalis stock reaches 52-week high at 16.42 USD - Investing.com
Personalis stock reaches 52-week high at 16.42 USD By Investing.com - Investing.com Canada
Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM) - Seeking Alpha
Personalis | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Personalis Inc : PSNL - 247wallst.com
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant - Yahoo Finance
Tempus AI Jumps 24% as Merck-Moderna mRNA Vaccine Win Lifts Personalis Deal - finance.biggo.com
TEM Stock Dips As Tempus AI Bets $1.5B On Personalis - StocksToTrade
Personalis Inc. (PSNL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
Tempus AI Stock Slides As $1.5B Personalis Bet Raises Stakes - timothysykes.com
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
What Personalis (PSNL)'s Rising Revenue But Deepening Losses Means For Shareholders - webull.com
Tempus Is Buying Cancer-Testing Partner Personalis for $1.5 Billion - RamaOnHealthcare
Ameriprise Financial (PSNL) discloses 5.8% ownership stake in Personalis common stock - Stock Titan
Deep Track Capital (PSNL) reports 4,000,000 Personalis shares, now under 5% ownership - Stock Titan
Sei Investments Co. Buys 83,040 Shares of Personalis, Inc. $PSNL - MarketBeat
Personalis, Inc. (PSNL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Personalis Inc (PSNL) Shares Fall 3.2% -- What GF Score of 53 Te - GuruFocus
Personalis, Inc. $PSNL Stock Holdings Lifted by Dimensional Fund Advisors LP - MarketBeat
Personalis (PSNL) Is Up 6.1% After Q2 Revenue Rises But Losses DeepenWhat's Changed - webull.com
TEM Surges Into $1.5B MRD Deal As Stock Pulls Back - StocksToTrade
Tempus AI Stock Drops As $1.5B Personalis Deal Ups The MRD Stakes - StocksToTrade
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Personalis Inc (PSNL) Stock News Today - TradingKey
Cancer Detection Test Receives Regulatory Marking for Use in Great Britain - Clinical Lab Products
Growth Potential For Personalis, Inc. (PSNL): A Look At Its 30% Revenue Surge - DirectorsTalk Interviews
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lake Street Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $16.25 - Moomoo
Personalis Reports Second Quarter 2026 Results and Recent Highlights - biospace.com
Is Personalis Inc (PSNL) Significantly Overvalued Even After Q2 Revenue of $22.4 Million? GF Score: 59/100 - GuruFocus
Personalis : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Personalis (NASDAQ:PSNL) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Personalis, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Personalis, Inc. Q2 2026: Revenue $22.36M, EPS $(0.30) — 10-Q Summary - TradingView
Earnings Flash (PSNL) Personalis, Inc. Reports Q2 Revenue $22.4M, vs. FactSet Est of $16.7M - marketscreener.com
Personalis Q2 revenue rises 30% to $22.4 million - Quiver Quantitative
Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage - TradingView
Personalis (NASDAQ: PSNL) posts larger loss and strikes Tempus cash-stock merger - Stock Titan
Personalis: Q2 Earnings Snapshot - marketscreener.com
Personalis Inc (PSNL) 財務データ
収益
当期純利益
現金流量
EPS
Personalis Inc (PSNL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chen Richard | President and CMO |
Jul 15 '26 |
Sale |
15.15 |
100,000 |
1,515,000 |
173,880 |
大文字化:
|
ボリューム (24 時間):